Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: Role of 124I-PET/CT and FDG-PET

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 35, Issue 5, 2008, Pages 950-957

  Freudenberg, L S ^a   Antoch, G ^a   Frilling, A ^a   Jentzen, W ^a   Rosenbaum, S J ^a   Kuhl H ^a   Bockisch, A ^a   Gorges R ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

Author keywords

124I; FDG; PET; PET CT; Thyroglobulin; Thyroid cancer

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IODINE 124; THYROGLOBULIN; THYROGLOBULIN ANTIBODY;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DISEASE FREE SURVIVAL; DRUG PENETRATION; DRUG UPTAKE; ECHOGRAPHY; FEMALE; HISTOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MALE; METASTASIS; POSITRON EMISSION TOMOGRAPHY; RECURRENT CANCER; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN BLOOD LEVEL; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA; THYROIDECTOMY;

ADULT; AGED; AGED, 80 AND OVER; FALSE NEGATIVE REACTIONS; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; THYROGLOBULIN; THYROID NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED;

EID: 42149175574     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-007-0634-8     Document Type: Article

References (29)

1. Frilling A, Görges R, Tecklenborg K, Gassmann P, Bockhorn M, Clausen M, et al. Value of preoperative diagnostic modalities in patients with recurrent thyroid carcinoma. Surgery 2000;128:1067-74.
2. Smallridge RC, Meek SE, Morgan MA, Gates GS, Fox TP, Grebe S, et al. Monitoring thyroglobulin in a sensitive immunoassay has comparable sensitivity to recombinant human tsh-stimulated thyroglobulin in follow-up of thyroid cancer patients. J Clin Endocrinol Metab 2007;92:82-7.
3. Gambhir SS, Czernin J, Schwimmer J, Silverman DH, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42:1S-93S.
4. Stokkel MP, Duchateau CS, Dragoiescu C. The value of FDG-PET in the follow-up of differentiated thyroid cancer: a review of the literature. Q J Nucl Med Mol Imaging 2006;50:78-87.
5. Freudenberg LS, Antoch G, Jentzen W, Pink R, Knust J, Görges R, et al. Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer. Eur Radiol 2004;14:2092-8.
6. Freudenberg LS, Bockisch A, Jentzen W. 124I Positron emission tomographic dosimetry and positron emission tomography/computed tomography imaging in differentiated thyroid cancer. In: Biersack HJ, Grünwald F, editors. Thyroid cancer 2nd edn. Berlin: Springer; 2005.
7. Jentzen W, Freudenberg L, Eising EG, Heinze M, Brandau W, Bockisch A. Segmentation of PET volumes by iterative image thresholding. J Nucl Med 2007;48:108-14.
8. Fleming ID, Cooper JS, Henson DE (eds) (1997) AJCC cancer staging manual. 5th edn. American Joint Committee on Cancer. Lippincott-Raven, Philadelphia.
9. 124I-PET dosimetry in advanced thyroid cancer: Therapeutic impact. Nuklearmedizin 2007;46:121-8.
10. Knust EJ, Dutschka K, Weinreich R. Preparation of 124I solutions after thermodistillation of irradiated 124TeO2 targets. Appl Radiat Isot 2000;52:181-84.
11. Antoch G, Kuehl H, Kanja J, Lauenstein TC, Schneemann H, Hauth E, et al. Dual modality PET/CT scanning with negative oral contrast agent to avoid artifacts: introduction and evaluation. Radiology 2004;230:879-85.
12. Furhang EE, Larson SM, Buranapong P, Humm JL, Furhang EE. Thyroid cancer dosimetry using clearance fitting. J Nucl Med 1999;40:131-36.
13. Maxon HR, Thomas SR, Samaratunga RC. Dosimetric considerations in the radioiodine treatment of macrometastases and micrometastases from differentiated thyroid cancer. Thyroid 1997;7:183-87.
14. Dietlein M, Dressler J, Farahati J, Grunwald F, Leisner B, Moser E, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 2). Nuklearmedizin. 2004;43:115-20.
15. Dietlein M, Dressler J, Eschner W, Leisner B, Reiners C, Schicha H.Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2). Nuklearmedizin 2003;42:123-5.
16. International Commission on Radiological Protection: Radiation dose to Patients from Radiopharmaceuticals, Publication 80. Oxford: Pergamon; 1999.
17. Frasoldati A, Pesenti M, Gallo M, Caroggio A, Salvo D, Valcavi R. Diagnosis of neck recurrences in patients with differentiated thyroid carcinoma. Cancer 2003 Jan 1;97(1):90-6.
18. Rosario PW, de Faria S, Bicalho L, Alves MF, Borges MA, Purisch S, et al. Ultrasonographic differentiation between metastatic and benign lymph nodes in patients with papillary thyroid carcinoma. J Ultrasound Med 2005;24:1385-9.
19. Torlontano M, Crocetti U, Augello G, D'Aloiso L, Bonfitto N, Varraso A, et al. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy. J Clin Endocrinol Metab 2006;91:60-3.
20. Görges R, Eising EG, Fotescu D, Renzing-Kohler K, Frilling A, Schmid KW, et al. Diagnostic value of high-resolution B-mode and power-mode sonography in the follow-up of thyroid cancer. Eur J Ultrasound 2003;16:191-206.
21. van den Brekel MW, Stel HV, Castelijns JA, Nauta JJ, van der Waal I, Valk J, et al. Cervical lymph node metastasis: assessment of radiological criteria. Radiology 1990;177:379-84.
22. Galloway RJ, Smallridge RC. Imaging in thyroid cancer. Endocrinol Metab Clin North Am 1996;25:93-113.
23. Freudenberg LS, Antoch G, Gorges R, Knust J, Pink R, Jentzen W, et al. Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report. Eur Radiol 2003;13:L19-23.
24. Grünwald F, Menzel C, Bender H, Palmedo H, Willkomm P, Ruhlmann J, et al. Comparison of F-18 FDG-PET with iodine-131 and Tc-99m-sestamibi scintigraphy in differentiated thyroid cancer. Thyroid 1997;7:327-35.
25. Wang W, Macapinlac H, Larson SM, Yeh SD, Akhurst T, Finn RD, et al. [18F]-2-fluoro-2-deoxy-d-glucose positron emission tomography localizes residual thyroid cancer in patients with negative diagnostic 131I whole body scans and elevated serum thyroglobulin levels. J Clin Endocrinol Metab 1999;84:2291-302.
26. Chung JK, So Y, Lee JS, Choi CW, Lim SM, Lee DS, et al. Value of FDG PET in papillary thyroid carcinoma with negative I-131 whole-body scan. J Nucl Med 1999;40:986-92.
27. Feine U, Lietzenmayer R, Hanke JP, Held J, Wohrle H, Muller-Schuenburg W. Fluorine-18-FDG and iodine-131-iodide uptake in thyroid cancer. J Nucl Med 1996;37:1468-72.
28. Grünwald F, Kalicke T, Feine U, Lietzenmayer R, Scheidhauer K, Dietlein M, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in thyroid cancer: results of a multicentre study. Eur J Nucl Med 1999;26:1547-52.
29. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60.